Open access data sharing from clinical trials: is it really feasible?

M. Flather
DOI: https://doi.org/10.1093/ehjqcco/qcv019
2015-11-01
European Heart Journal - Quality of Care and Clinical Outcomes
Abstract:Conducting randomized controlled trials (RCTs) of potentially effective treatments is time consuming and expensive, and for industry sponsored studies, the information is commercially sensitive. The notion that information from RCTs can be shared to ensure openness and transparency has been proposed by a number of groups, but at the present time there is no consensus on how data sharing should be carried out or the balance of benefit and risk inherent in this process.1–3 Naci et al .4 argue that providing original datasets from clinical trials in an open access anonymized format will avoid publication bias where ‘negative’ trials (which do not show a difference between treatment and control) have less chance of being published, resulting in important information not being available. Other reasons for making clinical trial data available are to improve reproducibility and validity, pool data across different studies to provide better estimates of treatment effects (especially … [↵][1]*Corresponding author. Tel: +44 759 539 2274/160 359 2693, Fax: +44 160 359 3752, Email: m.flather{at}uea.ac.uk [1]: #xref-corresp-1-1
What problem does this paper attempt to address?